Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line panitumumab monotherapy in frail elderly patients with KRAS wild-type advanced colorectal cancer
2009-016661-28Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-free survival at 6 months. Started Jan 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-016661-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016661-28.